Novartis, CH0012005267

Novartis ends Fabhalta trial while Novartis stock trades at EUR 134.82

Published on 10/19/2026 at 10:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fabhalta lupus nephritis study concludes for strategic reasons. Novartis stock costs EUR 134.82 on October 19, 2026 at Lang & Schwarz.

Fabhalta decision and Q2 figures

Novartis terminated a phase 2 Fabhalta study on October 19, 2026.
Second-quarter 2026 sales reached USD 14.40 billion with a 41.20 percent core operating margin.
Novartis stock trades at EUR 134.82 at 10:34 a.m. CEST at Lang & Schwarz on October 19, 2026.

Aquarell der Basler Altstadt mit Rheinbrücke und Münster in weichen Pastellfarben — Novartis AG CH0012005267 – Aquarell Basels mit Rheinbrücke und Münster in zarten Pastelltönen, Illustration mit AI erstellt.

Novartis (CH0012005267) terminated a phase 2 Fabhalta study in lupus nephritis on October 19, 2026, citing strategic considerations. Fidelity reported that Novartis said the decision was not driven by interim efficacy or safety findings, while other Fabhalta studies continue.

Fabhalta decision narrows one path

The terminated trial tested Fabhalta alongside standard care in lupus nephritis, a kidney complication of lupus. The study had completed its first part before Novartis notified investigators and began discussions with participants, according to Fidelity.

The news adds a specific development risk to a portfolio that delivered growth in the second quarter. In the companys investor materials, Novartis reported second-quarter 2026 net sales of USD 14.40 billion, up 3.00 percent in US dollars, while core operating income was USD 5.90 billion and flat year over year. The core operating margin was 41.20 percent, according to the published earnings-call transcript.

Three dates shape the next phase

Novartis received FDA approval for Rhapsido on October 7, 2026, as the first treatment for symptomatic dermographism. On October 2, 2026, it signed an Abogen licensing and option agreement worth up to USD 7.80 billion. The current Fabhalta decision came on October 19, 2026, with the phase 2 study termination confirmed by Ground News for the earlier agreement and by Novartis for the approval date.

What comes next for results

The next dated investor events are the Remibrutinib in MS investor call on October 23, 2026, and third-quarter results on October 27, 2026, both listed by Novartis. UBS maintained a Hold rating and a CHF 116.00 price target on October 15, 2026, according to Business Insider.

Stock price and investor calendar

The trial decision gives the October 27 results an additional pipeline angle, while the October 23 call offers an earlier read on remibrutinib development. At Lang & Schwarz, Novartis stock was trading at EUR 134.82 on October 19, 2026 at 10:34 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.